"These findings may inform shared decision making when considering GLP- 1 receptor agonist therapy and highlight the need for further evaluation of dermatological outcomes in future studies." The study involved a large number of people: 12,004 patients using GLP-1 drugs were compared to 15,221 using SGLT-2 inhibitors, with an additional 11,964 GLP-1 users compared to 11,233 using DPP-4 inhibitors
Acknowledgments Special thanks to the Guelph Research and Development Centre and Agriculture and Agri-Food Canada for providing the financial support and allocated resources for this project
if you have a lean or adrenal phenotype, you may benefit more from CoQ10, omega-3, and vitamin D
Surely, taking care of the skin is important not only to satisfy social needs but also to attend to biological health
In the Phase 2b VESPER program, weekly dosing achieved ~16% weight loss with no plateau through 32 weeks, successful transition to monthly maintenance, and favorable GI tolerability validating the feasibility of monthly GLP1 therapy
Lebrun, L
